CUTANEOUS HISTOPLASMOSIS IN A NEW DIAGNOSIS OF ADVANCED HIV

Pai Mangalore R¹, Cronin K¹, Moso MA¹, McMahon J^{1, 2}

Case Presentation: 41-year old man of Thai origin presented with a 3-week history of dry cough, fatigue, dyspnea, fevers, night sweats, intermittent diarrhea, unintentional weight-loss (18-kilograms) and mildly pruritic rash. His general practitioner diagnosed HIV and referred him for further management. He had no significant past medical history and tested negative for HIV 2-years prior.

On presentation he was cachectic, febrile (40°C), tachypnoeic and hypotensive (85/60 mmHg). He had a violaceous-brown papulosquamous rash, papules varying from 2-5 mm in size, some with central umbilication involving his face, neck, chest, abdomen and arms. Examination was otherwise unremarkable. Initial investigations revealed HIV viral load (VL) of 3.7 million copies /ml, CD4+ T-cell count of 14 cells/µL, multi-resistant *Salmonella spp.* on blood cultures, bilateral diffuse ground-glass opacification on CXR and positive *Pneumocystis jiroveci* (PJP) polymerase chain reaction (PCR) on sputum. He was treated with meropenem and trimethoprim/sulfamethoxazole, with significant improvement.

Punch biopsies of skin lesions showed scattered non-septate ovoid fungal elements, some showing schizogony, without true budding, within the dermis. The clinical concern was for penicilliosis, and treatment was commenced with conventional itraconazole (SporanoxTM) 200mg bd. Differential diagnoses included papular pruritic eruption, cutaneous cryptococcosis and dimorphic fungi.

Antiretroviral therapy was commenced at 2-weeks of PJP treatment (abacavir 600mg/lamivudine 300mg/dolutegarvir 50mg). Pan-fungal PCR and fungal culture of skin diagnosed *Histoplasma capsulatum*. Serum itraconazole trough level after one week was 0.33 mg/L (0.5–1.0mg/L). Itraconazole therapy was continued and compassionate access was gained for the more bioavailable itraconazole (LozanocTM) requiring dose reduction to 100mg bd. Two-months into treatment: VL was 130 copies/mL, CD4+ T cell count was 80 cells/µL, he had gained 8 kilograms was tolerating treatment and rash had improved significantly.

Histoplasmosis is a well-described endemic mycosis in advanced HIV and should be considered in people with rash and advanced HIV who have consistent epidemiological exposures.

Disclosure of Interest Statement:

JMs institution has received payment for his participation in advisory boards for Viiv Healthcare and Gilead Sciences.

¹Department of Infectious Diseases, The Alfred Hospital

²Monash University, Melbourne, Australia